XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
about
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsOxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodiesA bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerA bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model.TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells.Recent advances of bispecific antibodies in solid tumors.Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model.Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.Protegrin 1 Enhances Innate Cellular Defense via the Insulin-Like Growth Factor 1 Receptor Pathway
P2860
Q28072319-F35F1159-D456-4559-B0E0-7317FBF1D898Q28821982-C7FCD8B4-6D51-46B6-961A-D9D6F70E4755Q33689021-54DD1BC8-3F6B-47FC-ABF2-A658B009D2E8Q38651792-87A48EF3-D524-4717-85AC-A373D3EDD2D2Q38748906-6DBF36F8-F27A-48BD-9999-E03521B4825EQ39408469-80491DB4-5BDC-43DB-9ABB-847AFA61C33AQ41696278-64B20476-8098-4860-A051-74AD54CB603AQ41760366-08BDE497-0824-48A8-B609-D7E553C6C9F2Q47691851-6DDF2C04-C446-4253-8595-9A53DC3CB899Q50712468-8059CA29-6616-400A-98EF-4A81DE16364EQ57490046-89D5A7AC-FA57-4E9D-9F9B-E6283F889A4C
P2860
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
XGFR*, a novel affinity-mature ...... treatment of pancreatic cancer
@en
XGFR*, a novel affinity-mature ...... reatment of pancreatic cancer.
@nl
type
label
XGFR*, a novel affinity-mature ...... treatment of pancreatic cancer
@en
XGFR*, a novel affinity-mature ...... reatment of pancreatic cancer.
@nl
prefLabel
XGFR*, a novel affinity-mature ...... treatment of pancreatic cancer
@en
XGFR*, a novel affinity-mature ...... reatment of pancreatic cancer.
@nl
P2093
P2860
P1476
XGFR*, a novel affinity-mature ...... treatment of pancreatic cancer
@en
P2093
Carola H Ries
Christian Klein
Cuiying Shao
Ekkehard Moessner
Halina Trochanowska
Hubert Kettenberger
Juergen M Schanzer
Katharina Wartha
Marina Bacac
P2860
P304
P356
10.1080/19420862.2016.1160989
P577
2016-03-16T00:00:00Z